{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T14:31:26Z","timestamp":1749047486883,"version":"3.32.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,25]]},"DOI":"10.7759\/cureus.76371","type":"journal-article","created":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T15:30:57Z","timestamp":1735140657000},"source":"Crossref","is-referenced-by-count":1,"title":["Cost-Effectiveness and Clinical Outcomes of Controlled Ovarian Stimulation With Follitropin Delta and Follitropin Alfa: A Retrospective Study"],"prefix":"10.7759","author":[{"given":"Masato","family":"Kobanawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanako","family":"Iwami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masachi","family":"Hanaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Enatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuhiko","family":"Ichiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.328","article-title":"Different pharmacokinetic and pharmacodynamic properties of recombinant follicle-stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non-human cell line","volume":"54","author":"Olsson H","year":"2014","unstructured":"Olsson H, Sandstr\u00f6m R, Grundemar L. Different pharmacokinetic and pharmacodynamic properties of recombinant follicle-stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non-human cell line. J Clin Pharmacol. 2014, 54:1299-307. 10.1002\/jcph.328","journal-title":"J Clin Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/2.2.172","article-title":"Genetic engineering of human FSH (Gonal-F)","volume":"2","author":"Howles CM","year":"1996","unstructured":"Howles CM. Genetic engineering of human FSH (Gonal-F). Hum Reprod Update. 1996, 2:172-91. 10.1093\/humupd\/2.2.172","journal-title":"Hum Reprod Update"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1530\/EC-17-0067","article-title":"Comparative pharmacology of a new recombinant FSH expressed by a human cell line","volume":"6","author":"Koechling W","year":"2017","unstructured":"Koechling W, Plaksin D, Croston GE, Jeppesen JV, Macklon KT, Andersen CY. Comparative pharmacology of a new recombinant FSH expressed by a human cell line. Endocr Connect. 2017, 6:297-305. 10.1530\/EC-17-0067","journal-title":"Endocr Connect"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dev263","article-title":"Cumulative live birth rate: time for a consensus?","volume":"30","author":"Maheshwari A","year":"2015","unstructured":"Maheshwari A, McLernon D, Bhattacharya S. Cumulative live birth rate: time for a consensus?. Hum Reprod. 2015, 30:2703-7. 10.1093\/humrep\/dev263","journal-title":"Hum Reprod"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/hropen\/hoab022","article-title":"The Maribor consensus: report of an expert meeting on the development of performance indicators for clinical practice in ART","volume":"2021","author":"Vlaisavljevic V","year":"2021","unstructured":"Vlaisavljevic V, Apter S, Capalbo A, et al.. The Maribor consensus: report of an expert meeting on the development of performance indicators for clinical practice in ART. Hum Reprod Open. 2021, 2021:hoab022. 10.1093\/hropen\/hoab022","journal-title":"Hum Reprod Open"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2016.10.037","article-title":"How many oocytes are optimal to\u00a0achieve multiple live births with\u00a0one stimulation cycle? The\u00a0one-and-done approach","volume":"107","author":"Vaughan DA","year":"2017","unstructured":"Vaughan DA, Leung A, Resetkova N, Ruthazer R, Penzias AS, Sakkas D, Alper MM. How many oocytes are optimal to\u00a0achieve multiple live births with\u00a0one stimulation cycle? The\u00a0one-and-done approach. Fertil Steril. 2017, 107:397-404.e3. 10.1016\/j.fertnstert.2016.10.037","journal-title":"Fertil Steril"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2018.04.039","article-title":"Cumulative live birth rates according to the number of oocytes retrieved after the first ovarian stimulation for in\u00a0vitro fertilization\/intracytoplasmic sperm injection: a multicenter multinational analysis including \u223c15,000 women","volume":"110","author":"Polyzos NP","year":"2018","unstructured":"Polyzos NP, Drakopoulos P, Parra J, et al.. Cumulative live birth rates according to the number of oocytes retrieved after the first ovarian stimulation for in\u00a0vitro fertilization\/intracytoplasmic sperm injection: a multicenter multinational analysis including \u223c15,000 women. Fertil Steril. 2018, 110:661-70.e1. 10.1016\/j.fertnstert.2018.04.039","journal-title":"Fertil Steril"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0529-567X.2018.03.004","article-title":"Cumulative live birth rates per oocytes retrieved cycle: evaluation of clinical outcomes of IVF\/ICSI","volume":"53","author":"Wu CX","year":"2018","unstructured":"Wu CX, Zhang T, Shu L, et al.. Cumulative live birth rates per oocytes retrieved cycle: evaluation of clinical outcomes of IVF\/ICSI. Zhonghua Fu Chan Ke Za Zhi. 2018, 53:160-6. 10.3760\/cma.j.issn.0529-567X.2018.03.004","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.23736\/S0026-4784.18.04347-2","article-title":"Cumulative live birth rates in in-vitro fertilization","volume":"71","author":"Drakopoulos P","year":"2019","unstructured":"Drakopoulos P, Err\u00e1zuriz J, Santos-Ribeiro S, et al.. Cumulative live birth rates in in-vitro fertilization. Minerva Ginecol. 2019, 71:207-10. 10.23736\/S0026-4784.18.04347-2","journal-title":"Minerva Ginecol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deg181","article-title":"A prospective study of predictive factors of ovarian response in 'standard' IVF\/ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage normogram","volume":"18","author":"Popovic-Todorovic B","year":"2003","unstructured":"Popovic-Todorovic B, Loft A, Lindhard A, Bangsb\u00f8ll S, Andersson AM, Andersen AN. A prospective study of predictive factors of ovarian response in 'standard' IVF\/ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage normogram. Hum Reprod. 2003, 18:781-7. 10.1093\/humrep\/deg181","journal-title":"Hum Reprod"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X104678","article-title":"Predictive factors and a corresponding treatment algorithm for controlled ovarian stimulation in patients treated with recombinant human follicle stimulating hormone (follitropin alfa) during assisted reproduction technology (ART) procedures. An analysis of 1378 patients","volume":"22","author":"Howles CM","year":"2006","unstructured":"Howles CM, Saunders H, Alam V, Engrand P. Predictive factors and a corresponding treatment algorithm for controlled ovarian stimulation in patients treated with recombinant human follicle stimulating hormone (follitropin alfa) during assisted reproduction technology (ART) procedures. An analysis of 1378 patients. Curr Med Res Opin. 2006, 22:907-18. 10.1185\/030079906X104678","journal-title":"Curr Med Res Opin"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2011.11.014","article-title":"Targeted gonadotrophin stimulation using the PIVET algorithm markedly reduces the risk of OHSS","volume":"24","author":"Yovich J","year":"2012","unstructured":"Yovich J, Stanger J, Hinchliffe P. Targeted gonadotrophin stimulation using the PIVET algorithm markedly reduces the risk of OHSS. Reprod Biomed Online. 2012, 24:281-92. 10.1016\/j.rbmo.2011.11.014","journal-title":"Reprod Biomed Online"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dex219","article-title":"Non-equivalence of anti-M\u00fcllerian hormone automated assays-clinical implications for use as a companion diagnostic for individualised gonadotrophin dosing","volume":"32","author":"Iliodromiti S","year":"2017","unstructured":"Iliodromiti S, Salje B, Dewailly D, et al.. Non-equivalence of anti-M\u00fcllerian hormone automated assays-clinical implications for use as a companion diagnostic for individualised gonadotrophin dosing. Hum Reprod. 2017, 32:1710-5. 10.1093\/humrep\/dex219","journal-title":"Hum Reprod"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/s1472-6483(10)60042-9","article-title":"Symposium: Update on prediction and management of OHSS. A modern classification of OHSS","volume":"19","author":"Golan A","year":"2009","unstructured":"Golan A, Weissman A. Symposium: Update on prediction and management of OHSS. A modern classification of OHSS. Reprod Biomed Online. 2009, 19:28-32. 10.1016\/s1472-6483(10)60042-9","journal-title":"Reprod Biomed Online"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/00001703-199906000-00013","article-title":"Culture and transfer of human blastocysts","volume":"11","author":"Gardner DK","year":"1999","unstructured":"Gardner DK, Schoolcraft WB. Culture and transfer of human blastocysts. Curr Opin Obstet Gynecol. 1999, 11:307-11. 10.1097\/00001703-199906000-00013","journal-title":"Curr Opin Obstet Gynecol"},{"key":"ref16","unstructured":"Public Expenditure for Pregnancy Health Examinations. (2024). Accessed. August 2024: https:\/\/www.mhlw.go.jp\/stf\/houdou\/0000176691_00004.html."},{"key":"ref17","unstructured":"Current Status of Support for Expectant and Nursing Mothers, etc. in the Medical Insurance System. Accessed. April 1, 2022: https:\/\/www.mhlw.go.jp\/content\/12401000\/001267928.pdf."},{"key":"ref18","unstructured":"Medical Insurance System in Japan [A2]. https.\/\/www.kyoukaikenpo.or.jp\/."},{"key":"ref19","unstructured":"Analysis Guidelines for Cost-Effectiveness Evaluation at the Central Social Insurance Medical Council. (2024). Accessed. August 20, 2024: https:\/\/c2h.niph.go.jp\/tools\/guideline\/guideline_ja.pdf."},{"key":"ref20","article-title":"An Introduction to the Bootstrap","author":"Efron B","year":"1993","unstructured":"Efron B. An Introduction to the Bootstrap. Chapman & Hall, New York; 1993."},{"key":"ref21","unstructured":"Japan Health Insurance Association. When We Paid Large Amount of Medical Expenses (Large Amount of Medical Expenses). (2024). Accessed. August 2024: https:\/\/www.kyoukaikenpo.or.jp\/g3\/sb3030\/r150\/."},{"key":"ref22","unstructured":"World Intellectual Property Organization (WO 2009\/127826 A1) Recombinant FSH Including Alfa 2,3 and Alfa 2,6 Sialylation. (2024). Accessed. August 2024: https:\/\/patentimages.storage.googleapis.com\/26\/4e\/14\/7e6587a3cf7f8d\/WO2009127826A1.pdf."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24109020","article-title":"Follicle-stimulating hormone biological products: does potency predict clinical efficacy?","volume":"24","author":"Lispi M","year":"2023","unstructured":"Lispi M, Humaidan P, Bousfield GR, D'Hooghe T, Ulloa-Aguirre A. Follicle-stimulating hormone biological products: does potency predict clinical efficacy?. Int J Mol Sci. 2023, 24:10.3390\/ijms24109020","journal-title":"Int J Mol Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2021.01.023","article-title":"Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF\/ICSI patients: a randomized controlled trial","volume":"42","author":"Ishihara O","year":"2021","unstructured":"Ishihara O, Arce JC. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF\/ICSI patients: a randomized controlled trial. Reprod Biomed Online. 2021, 42:909-18. 10.1016\/j.rbmo.2021.01.023","journal-title":"Reprod Biomed Online"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2016.10.033","article-title":"Individualized versus conventional ovarian stimulation for in\u00a0vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial","volume":"107","author":"Nyboe Andersen A","year":"2017","unstructured":"Nyboe Andersen A, Nelson SM, Fauser BC, Garc\u00eda-Velasco JA, Klein BM, Arce JC. Individualized versus conventional ovarian stimulation for in\u00a0vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril. 2017, 107:387-96.e4. 10.1016\/j.fertnstert.2016.10.033","journal-title":"Fertil Steril"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deab155","article-title":"A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF\/ICSI patients","volume":"36","author":"Qiao J","year":"2021","unstructured":"Qiao J, Zhang Y, Liang X, et al.. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF\/ICSI patients. Hum Reprod. 2021, 36:2452-62. 10.1093\/humrep\/deab155","journal-title":"Hum Reprod"},{"key":"ref27","article-title":"Comparative study of clinical results and cost-effectiveness of controlled ovarian stimulation using follitropin alfa and follitropin delta","volume":"40","author":"Kobanawa M","year":"2023","unstructured":"Kobanawa M, Yoshida J. Comparative study of clinical results and cost-effectiveness of controlled ovarian stimulation using follitropin alfa and follitropin delta. J Fert Implant. 2023, 40:23-32.","journal-title":"J Fert Implant"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-016-0259-9","article-title":"Economic evaluation of three frequently used gonadotrophins in assisted reproduction techniques in the management of infertility in the Netherlands","volume":"14","author":"Fragoulakis V","year":"2016","unstructured":"Fragoulakis V, Pescott CP, Smeenk JM, van Santbrink EJ, Oosterhuis GJ, Broekmans FJ, Maniadakis N. Economic evaluation of three frequently used gonadotrophins in assisted reproduction techniques in the management of infertility in the Netherlands. Appl Health Econ Health Policy. 2016, 14:719-27. 10.1007\/s40258-016-0259-9","journal-title":"Appl Health Econ Health Policy"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.09.326","article-title":"Cost minimisation analysis of Follitropin Delta versus follitropin alfa in assisted reproductive technologies (ivf\/Icsi) in the United Kingdom","volume":"19","author":"Sivignon M","year":"2016","unstructured":"Sivignon M, Palencia R, Roze S. Cost minimisation analysis of Follitropin Delta versus follitropin alfa in assisted reproductive technologies (ivf\/Icsi) in the United Kingdom. Value Health. 2016, 19:403. 10.1016\/j.jval.2016.09.326","journal-title":"Value Health"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-01768-w","article-title":"Effects of total gonadotropin dose on embryo quality and clinical outcomes with AMH stratification in IVF cycles: a retrospective analysis of 12,588 patients","volume":"29","author":"Shen X","year":"2024","unstructured":"Shen X, Guo Y, Liu Y, Song W, Li G, Jin H. Effects of total gonadotropin dose on embryo quality and clinical outcomes with AMH stratification in IVF cycles: a retrospective analysis of 12,588 patients. Eur J Med Res. 2024, 29:167. 10.1186\/s40001-024-01768-w","journal-title":"Eur J Med Res"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2008.01.012","article-title":"A high oocyte yield for intracytoplasmic sperm injection treatment is associated with an increased chromosome error rate","volume":"91","author":"Haaf T","year":"2009","unstructured":"Haaf T, Hahn A, Lambrecht A, et al.. A high oocyte yield for intracytoplasmic sperm injection treatment is associated with an increased chromosome error rate. Fertil Steril. 2009, 91:733-8. 10.1016\/j.fertnstert.2008.01.012","journal-title":"Fertil Steril"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dex299","article-title":"High gonadotropin dosage does not affect euploidy and pregnancy rates in IVF PGS cycles with single embryo transfer","volume":"32","author":"Barash OO","year":"2017","unstructured":"Barash OO, Hinckley MD, Rosenbluth EM, Ivani KA, Weckstein LN. High gonadotropin dosage does not affect euploidy and pregnancy rates in IVF PGS cycles with single embryo transfer. Hum Reprod. 2017, 32:2209-17. 10.1093\/humrep\/dex299","journal-title":"Hum Reprod"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deaa028","article-title":"No effect of ovarian stimulation and oocyte yield on euploidy and live birth rates: an analysis of 12\u2009298 trophectoderm biopsies","volume":"35","author":"Irani M","year":"2020","unstructured":"Irani M, Canon C, Robles A, et al.. No effect of ovarian stimulation and oocyte yield on euploidy and live birth rates: an analysis of 12\u2009298 trophectoderm biopsies. Hum Reprod. 2020, 35:1082-9. 10.1093\/humrep\/deaa028","journal-title":"Hum Reprod"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s10815-017-0909-3","article-title":"The cumulative dose of gonadotropins used for controlled ovarian stimulation does not influence the odds of embryonic aneuploidy in patients with normal ovarian response","volume":"34","author":"Sekhon L","year":"2017","unstructured":"Sekhon L, Shaia K, Santistevan A, Cohn KH, Lee JA, Beim PY, Copperman AB. The cumulative dose of gonadotropins used for controlled ovarian stimulation does not influence the odds of embryonic aneuploidy in patients with normal ovarian response. J Assist Reprod Genet. 2017, 34:749-58. 10.1007\/s10815-017-0909-3","journal-title":"J Assist Reprod Genet"},{"key":"ref35","unstructured":"Ministry of Health, Labor and Welfare Initiatives for Fertility Treatment. (2022). Accessed. April 2022: https:\/\/www.cfa.go.jp\/policies\/boshihoken\/funin ."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/329009-cost-effectiveness-and-clinical-outcomes-of-controlled-ovarian-stimulation-with-follitropin-delta-and-follitropin-alfa-a-retrospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T15:31:00Z","timestamp":1735140660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/329009-cost-effectiveness-and-clinical-outcomes-of-controlled-ovarian-stimulation-with-follitropin-delta-and-follitropin-alfa-a-retrospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,25]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.76371","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,25]]}}}